A Randomized Phase II Study of Pembrolizumab With or Without Defactinib, a Focal Adhesion Kinase Inhibitor Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Defactinib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 01 Feb 2019 Planned End Date changed from 1 Jan 2023 to 1 Feb 2023.
- 01 Feb 2019 Planned primary completion date changed from 1 Jan 2023 to 1 Feb 2023.
- 01 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Feb 2019.